Trials
3 active
4 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.”In the company’s words, NCT05475925 on ClinicalTrials.gov
- Tested for
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder and 13 more
- Main trialPhase 1/2
- “This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas”In the company’s words, NCT05475925 on ClinicalTrials.gov
- Other names
- DR-01
Other drugs for Hepatosplenic T-cell Lymphoma
- GlofitamabRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- TocilizumabRoche · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- XNW5004Evopoint Biosciences Inc. · Phase 3
Coming up3
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- May 2027Phase 1 trial completes · ClinicalTrials.gov
- Apr 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2026 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | |
| Phase 1/2Recruiting | Apr 2029 | A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes | |
| Phase 1Active, not recruiting | May 2027 | A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | |
| Phase 1Completed | 27 Aug 2025 | A Study of Subcutaneous DR-01 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026